Phaseline

Companies › Oxion Biologics

Oxion Biologics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OX118
human monoclonal antibody targeting OX40 ligand (OX40L)
TNFSF4Phase 1Immune System–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07020156OX118Phase 1Immune SystemImmunologyOct 2025

Targets

TNFSF4 (1)

Companies with the same targets

Sanofi

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.